• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

LGC Acquires Toronto Research Chemicals, Strengthening Presence in Reference Standards Market

Share:

August 19, 2019

Today, LGC announced the acquisition of a majority stake in Toronto Research Chemicals (“TRC”), a leading manufacturer and supplier of synthetic organic bio-chemicals which are used as reference standards, research tools and building blocks by a highly diversified global customer base across the pharmaceutical, applied and research sectors.

TRC has a leading market position supported by an extensive product portfolio with over 46,000 compounds held in inventory and a wide breadth of synthetic and analytical chemistry capabilities. Founded in 1982 by David and Charles Dime, TRC has over 375 employees and operates from c.120,000 square foot of space across two manufacturing sites in Toronto.

The acquisition of TRC complements LGC’s existing reference standards business, which includes the MikromolTM and Dr EhrenstorferTM product portfolios, and provides commercial and operational opportunities to develop the combined product and service offering to customers globally.

TRC’s Chief Executive Charles Dime will remain a significant shareholder alongside LGC.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Euan O’Sullivan, Managing Director, LGC’s Standards division, said, “We are delighted to partner with TRC to deliver the next phase of growth in the business and expansion of capabilities in Toronto. We have enjoyed a long and successful relationship with TRC and this transaction strengthens our presence in the reference standards market, in particular in North America and Asia Pacific, as well as our ability to serve pharmaceutical and biotech customers. As we start combining our teams, we look forward to providing an extended portfolio of reference standards, research tools and building blocks to our customers around the world.”

David and Charles Dime, Co-Founders, TRC, said, “We are excited to be partnering with LGC and continuing to provide our customers with high quality products and services. Over the years, we have built a strong reputation as a supplier of choice for customers globally and look forward to strengthening our capabilities and product offering alongside LGC.”

Date: August 19, 2019

Source: LGC Group

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Top 10 Biopharma IPOs of January—June 2018Top 10 Biopharma IPOs of January—June 2018
  • Oura Ring Detects the Onset of Fever, a Common COVID-19 SymptomOura Ring Detects the Onset of Fever, a Common COVID-19 Symptom
  • VA Diffusion Of Excellence Lead On How The VHA’s Innovator’s Network Is Transforming Veteran CareVA Diffusion Of Excellence Lead On How The VHA’s Innovator’s Network Is Transforming Veteran Care
  • Revive Therapeutics Acquires Unique Psilocybin AssetsRevive Therapeutics Acquires Unique Psilocybin Assets
  • Johnson & Johnson under Pressure as FDA Approves New use for XareltoJohnson & Johnson under Pressure as FDA Approves New use for Xarelto
  • 3 Use Cases for Artificial Intelligence in Healthcare3 Use Cases for Artificial Intelligence in Healthcare
  • RefleXion Medical Raises $125M for Biology-Guided RadiotherapyRefleXion Medical Raises $125M for Biology-Guided Radiotherapy
  • NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger AgreementNTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement

Trending This Week

  • New tools and acquisitions from OptumRx, ScionHealth.
  • In the wake of Dobbs, women’s health is ‘Ripe for investment’
  • Market Skeptical Following Sen. Warren’s Antitrust Allegations
  • Rogers, Shaw tick lower amid a report that Industry Minister in no hurry to Ok deal
  • ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, furthering its Ambition to Become the Global Leader in Regenerative Therapies
  • LGM Pharma Acquires Pharmaceutical Development and Manufacturing Unit of Nexgen Pharma

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications